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PNL12
TRIPTANS FOR MIGRAINE THERAPY:A COMPARISON BASED
ON NUMBER NEEDED TO TREAT AND DOSES NEEDED 
TO TREAT
Mullins CD1,Weis KA2, Perfetto EM3, Subedi P1, Healey PJ2
1University of Maryland School of Pharmacy, Baltimore, MD, USA;
2Pﬁzer, Inc, New York, NY, USA; 3The Weinberg Group, Inc,
Washington, DC, USA
OBJECTIVES: Managed care and other decision makers need
sound comparative information to support the formulary selec-
tion process and reimbursement decisions for the treatment of
migraine. The objective of this study was to compare currently
marketed triptan therapies using number-needed-to-treat (NNT)
and doses-needed-to-treat (DNT) measures. DNT was further
used to derive triptan treatment cost to achieve 100 successfully
treated patients. METHODS: Using published meta-analysis
data to categorize patients as treatment success or failure, an
NNT and a DNT were derived for each triptan. Treatment
success was deﬁned as achieving a two-hour pain response, sus-
tained through 24 hours postdose. Costs were derived by multi-
plying DNT by the average wholesale price subtracted by 15%
for each triptan. RESULTS: Eletriptan 40mg had the lowest
NNT, with 361 patients needing to be treated in order to have
100 patients achieve clinical beneﬁt. Rizatriptan 5mg had the
highest NNT (597 patients). Eletriptan 40mg required 389 
doses to successfully treat 100 patients—the lowest number of
doses of the triptans considered; rizatriptan 5mg required the
highest number (662 doses). Eletriptan 40mg had the lowest
total triptan cost of $5639 to successfully treat 100 patients. 
The highest total triptan cost of treatment was for naratriptan
2.5mg, at a cost of $11,144. CONCLUSIONS: Eletriptan 
40mg provides the best value in terms of the lowest DNT.
Eletriptan 40mg also was found to have the lowest total 
triptan cost to successfully treat 100 patients. Future research
should further explore the utility of DNT in managed care 
decision-making.
PNL13
COST-EFFECTIVENESS OF ELETRIPTAN VERSUS
ZOLMITRIPTAN: RESULTS FROM A RANDOMIZED
CONTROLLED TRIAL
Mullins CD1, Healey PJ2, Mychaskiw MA2, Meng F1,Weis KA2
1University of Maryland School of Pharmacy, Baltimore, MD, USA;
2Pﬁzer, Inc, New York, NY, USA
OBJECTIVES: The objective of this study was to compare the
cost-effectiveness of eletriptan to zolmitriptan using 24-hour 
sustained headache pain response as the measure of migraine
treatment outcome. METHODS: This economic analysis was
based on data derived from a randomized, multi-center, double-
blind, double-dummy, parallel group, placebo controlled, single-
attack study of treatment for acute migraine. Patients enrolled
in the clinical trial were randomized to eletriptan 40mg,
zolmitriptan 2.5mg, or placebo. The clinical efﬁcacy data from
the two active treatment arms were combined with published
drug cost data to assess the relative cost-effectiveness of eletrip-
tan versus zolmitriptan. The cost per successfully treated patient
(CPSTP) was calculated for both treatment groups as the ratio
of the total triptan cost for treating all patients to the number of
patients classiﬁed as being successfully treated. The health
authority costs included eletriptan 40mg at 3.40€ per dose and
zolmitriptan 2.5mg at 3.58€ per dose. The 24-hour sustained
headache pain response rate was the effectiveness measure used
in the denominator of the CPSTP ratio. RESULTS: For the 24-
hour sustained headache pain response measure, a signiﬁcantly
larger proportion of patients were successfully treated with
eletriptan versus zolmitriptan (p = 0.0099). The CPSTP estimates
were 10.34€ (95% CI: 8.97€–12.17€) for eletriptan and 14.65€
(95% CI: 12.53€–17.45€) for zolmitriptan. CONCLUSIONS:
For the 24-hour sustained headache response endpoint, eletrip-
tan 40mg performed signiﬁcantly better than zolmitriptan 
2.5mg. For the cost per successfully treated patient, eletriptan
costs were signiﬁcantly lower compared to zolmitriptan costs.
The results of this study add to the body of clinical and economic
evidence supporting the use of eletriptan for the treatment of
acute migraine, and can be used to assist decision makers in the
allocation of scarce resources.
PNL14
IMPACT OF MIGRAINE FREQUENCY ON HEALTH UTILITIES
Brown J1, Neumann P2, Papadopoulos G3, Ruoff G4, Maizels M5,
Diamond M6, Menzin J1
1Boston Health Economics, Waltham, MA, USA; 2Harvard University,
Boston, MA, USA; 3Johnson & Johnson Pharmaceutical Services LLC,
Raritan, NJ, USA; 4Westside Family Medical Center, Kalamazoo, MI,
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OBJECTIVES: To relate migraine frequency to general health
status among a cohort of migraineurs. METHODS: We con-
ducted a cross-sectional survey of patients aged ≥ 18 years 
diagnosed with episodic migraine (and no migraine at time of
recruitment) and ≥ one-year of migraine history. Patients were
enrolled at three geographically diverse US centers representing
varied models of care. Subjects completed a questionnaire that
included demographic/clinical information and the Health Utili-
ties Index Mark three (HUI3). Multivariate analyses were under-
taken to assess the relationship between HUI3 and migraine
frequency, controlling for study center, demographics (age, sex,
income) and clinical characteristics (comorbidities, migraine
severity, presence of aura, duration, disruptiveness of migraine
to family and friends). RESULTS: The mean age of subjects (n
= 150) was 44 years and 87% were female. Patients averaged 24
years of migraine history, and 41% reported using preventive
medication. Mean (±SD) monthly migraine frequency was 4.4
(±3.6), with 34% reporting £ two migraines per month and 20%
reporting > six per month. Mean (±SD) HUI3 score was 0.62
(±0.26) and the median was 0.66. Migraine frequency was sig-
niﬁcantly (p < 0.05) and negatively associated with HUI3 scores.
Adjusted mean HUI3 score was 0.64 for those with £ two
migraines per month, 0.57 for those with > two to four migraines
per month, 0.53 for those with > four to six migraines per
month, and 0.50 for those with > six migraines per month.
Migraine frequency was positively associated with higher levels
of impairment on the emotion, cognition, and pain components
of the HUI3. CONCLUSIONS: Migraineurs suffer substantial
impairment in health utility, with more frequent migraines asso-
ciated with greater impairment. These utility data are useful for
assessing the burden of migraine headache, and for evaluating
the impact and cost-effectiveness of interventions that reduce the
rate of migraine attacks.
PNL15
FURTHER VALIDATION OF THE MIGRAINE TREATMENT
SATISFACTION MEASURE
Martin ML1, Patrick DL2, Bushnell DM1, Gandra SR1, Pesa J3
1Health Research Associates, Mountlake Terrace, WA, USA;
2University of Washington, Seattle, WA, USA; 3AstraZeneca LP,
Wilmington, DE, USA
OBJECTIVE: Initial development of a new measure for assess-
ing patient satisfaction with treatment for migraine headaches
utilizes a four-part conceptual model incorporating patient
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expectations and preferences with self-reported outcomes and
satisfaction. In this report we evaluate the psychometric perfor-
mance of the Migraine Treatment Satisfaction measure (MTS)
using participants from a randomized controlled trial of
headache management. METHODS: Enrolled migraineurs com-
pleted the ﬁrst two modules of the MTS upon enrollment in the
treatment program and the ﬁnal two modules at six-months.
Internal consistency reliability was computed within each of the
four modules. Discriminant validity was ascertained by compar-
ison with the Migraine Disability Assessment Questionnaire
(MIDAS), Patient Health Questionnaire (PHQ-9), and Migraine
Symptom Frequency and Bothersomeness (MSFB) scores. For
convergent validity, Pearson’s correlation was used to measure
associations between MTS scores, general health status (SF-36),
MIDAS and MSFB. RESULTS: Overall, 124 migraineurs (mean
age 45.4 years, 75% women, 54.1% Caucasian) were enrolled.
Internal consistency statistics for the expectations, outcomes,
importance ratings, and satisfaction measures were within
acceptable ranges (0.83, 0.86, 0.85, and 0.95, respectively) and
were consistent with earlier development work for this measure.
Satisfaction (MTS) decreased signiﬁcantly as depression (PHQ-
9 scores) increased. MTS scores by symptom bothersomeness 
tertiles and symptom frequency tertiles showed a signiﬁcant
decrease in satisfaction among those experiencing moderate-
severe symptom bothersomeness and symptom frequency.
Derived MTS scores showed strong associations with MSFB
scores (-0.301; p < 0.01), MIDAS (-0.267; p < 0.01), general
health (0.253; p < 0.05), mental health (0.217; p < 0.05) and
vitality subscales of SF-36 (0.214; p < 0.05). Patients on triptans
reported a signiﬁcantly higher satisfaction compared to patients
on analgesics (39.5 vs. 32.9; p < 0.05). CONCLUSION: MTS
can be considered as a valuable instrument to be used for the
description of migraine treatment satisfaction.
PNL16
DEVELOPMENT OF A UNIQUE INTERNET & PHONE BASED
SYSTEM TO CAPTURE MIGRAINE TREATMENT OUTCOMES
Ambegaonkar AJ, Holdsworth K, Livengood KB,Vlasnik J,Tiseo PJ
Pﬁzer Inc, New York, NY, USA
OBJECTIVES: To develop a patient-reported outcomes data col-
lection system using the internet or the telephone for migraine
patients being treated with Relpax (eletriptan HBr). METHODS:
Physicians provided medication and study information to 
eligible migraine patients in their practice willing to participate.
Patients were able to access the data collection system (The
Relpax Challenge), either via the Internet or an interactive voice
response system (IVR). Patient kits contained preprinted ID
numbers that mapped them to their physicians. Upon enrolling,
migraineurs answered a baseline survey of demographic infor-
mation, migraine experience and associated health care utiliza-
tion, and a prior migraine medication satisfaction survey.
Following the baseline survey, patients were then asked to rate
their satisfaction to treatment for three subsequent Relpax
treated migraine attacks. Data was collected over an SSL pro-
tected website and stored in a SQL server database. The website
was developed using Macromedia and ensured a user-friendly
environment for data entry. The IVR also reposited data into the
same data warehouse. RESULTS: Currently 3604 registered
patients have completed questionnaires for 5837 Relpax treated
attacks. The majority of the respondents were female (87.53%)
with an average age of 37.5 years. Forty-four percent completed
data on all three attacks, of which 93.1% indicated that they
would take Relpax again. Migraineurs were satisﬁed (four or ﬁve
on a ﬁve point scale) with their relief of pain (70.20%), speed of
relief (60.10%), relief of nausea (50.91%), relief of sensitivity to
light (58.10%), relief of sensitivity to sound (57.29%) and their
ability to return to their day (57.29%). CONCLUSIONS: Uti-
lizing this technology, we have created a reliable and easy-to-use
internet and phone based system for collecting patient reported
outcomes. Satisfaction with Relpax treatment as well as other
treatment outcomes were consistent with the results observed in
the Relpax clinical trials.
NEUROLOGICAL DISORDERS—Multiple Sclerosis
PNL17
EFFECT OF IMMUNOMODULATORY THERAPY AND OTHER
FACTORS ON PRODUCTIVITY IN MS
Lage MJ1, Castelli-Haley J2, Oleen-Burkey M2
1HealthMetrics Outcomes Research, Groton, CT, USA; 2Teva
Neuroscience, Kansas City, MO, USA
OBJECTIVE: Examine factors that inﬂuence work days missed
among employees diagnosed with multiple sclerosis (MS).
METHODS: This retrospective analysis used a claims database
with inpatient and outpatient visits, prescription drug services,
and time missed from work for the years 1999 through 2002.
Employees with a diagnosis of MS were identiﬁed and examined
over the calendar year of ﬁrst observed diagnosis in the database
(N = 284). Multivariate regressions controlling for demogra-
phic characteristics, overall severity of illness, and type of
immunomodulatory medication examined factors that inﬂuence
days missed from work. RESULTS: Demographic characteristics,
overall severity of illness, and type of immunomodulatory
therapy all impacted time missed from work. Individual comor-
bid diagnoses had no impact on time missed from work. 
Comparing individuals treated with interferon beta-1a (intra-
muscular), interferon beta-1b, or the speciﬁc immunomodulator
glatiramer acetate to those who received no treatment for MS
revealed that only glatiramer acetate was associated with signif-
icantly fewer days missed from work for short term disability
(18.24 fewer days, p = 0.03), worker’s compensation (29.50
fewer days, p = 0.04) or any reason (53.70 fewer days, p =
0.003). Average wage estimates of $22.18i and research that
reveals productivity lost due to absence averages 1.61 times the
wageii suggest an annual productivity savings of $15,340 asso-
ciated with glatiramer acetate. CONCLUSIONS: Demographic
characteristics and overall severity of illness impact time missed
from work for employees diagnosed with MS. Only MS treat-
ment with glatiramer acetate was associated with signiﬁcantly
fewer days of work missed.
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THE IMPACT OF MEDICARE PART D ON ECONOMIC
BARRIERS TO PRESCRIPTION MEDICATIONS AMONG
BENEFICIARIES WITH MULTIPLE SCLEROSIS
Lundy JJ, Craig BM
University of Arizona,Tucson, AZ, USA
OBJECTIVES: 1) Identify the prevalence of access barriers to
prescription medications among beneﬁciaries with Multiple Scle-
rosis (MS); and 2) estimate the out of pocket price of commonly
used prescription medications among insured and under-insured
MS beneﬁciaries. METHODS: Using claims data from the
Medicare Current Beneﬁciary Survey (MCBS) 1992–2001, we
identiﬁed 156 beneﬁciaries with a diagnosis of multiple sclerosis
on four or more claims (ICD-9 340). The MCBS is an overlap-
ping panel survey linked to associate claims that includes ques-
tions on out-of-pocket price, access, and use of prescription
medications. We estimated the average out-of-pocket price of
prescription medications and prevalence of perceived economic
barriers to address the hypothesis that the expansion of Medicare
